Abstracts tagged "outcomes"

Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 1259 • 2018 ACR/ARHP Annual Meeting
Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review
Daniel Zhou¹, Ted R. Mikuls², Cynthia Schmidt³, Bryant R. England⁴, Debra A Bergman⁵, Matthew Rizzo⁶, Jennifer Merickel⁶ and Kaleb Michaud^7,8, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁷Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Automobile driving represents an instrumental activity of daily living (IADL). Symptoms accompanying RA, including fatigue, joint pain and stiffness, decreased strength, reduced mobility, and…
Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
William Stohl¹, Milena Kurtinecz², Joe Eastman³, Vanessa Castellano⁴, Chrysa Mahoney⁴, Tania Gonzalez-Rivera² and Bonnie Pobiner⁴, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²GlaxoSmithKline, Philadelphia, PA, ³GlaxoSmithKline (at the time of the study), Research Triangle Park, NC, ⁴GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…
Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
Haiting Wang¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye², ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Juan Gabriel Ovalles-Bonilla^1,2, Francisco Javier López Longo³, Iñigo Rúa-Figueroa⁴, María Galindo⁵, Jaime Calvo-Alén⁶, Juan Carlos Nieto², Julia Martínez-Barrio³, Roberto González⁷, Belen Serrano⁸, Iustina Janta², Carlos M Gonzalez⁹, Indalecio Monteagudo² and JM Pego-Reigosa¹⁰, ¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ⁷Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁹Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…
Abstract Number: 348 • 2017 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome
Irazú Contreras-Yáñez¹, Guillermo Guaracha², César Sifuentes-Cantú³ and Virginia Pascual-Ramos⁴, ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico
Background/Purpose: Sustained remission (SR) is the most desirable status in patients with rheumatoid arthritis (RA). For adoption by patients, SR should reflect symptom´s resolution and…
Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Dimitrios A. Pappas¹, Chitra Karki¹, Ying Shan¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…
Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
Abstract Number: 781 • 2017 ACR/ARHP Annual Meeting
A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
Valentin S. Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Christina Duftner⁴, Annamaria Iagnocco⁵, George A. W. Bruyn⁶, Greta Carrara⁷, MA D'Agostino⁸, Eugenio De Miguel⁹, Andreas P Diamantopoulos¹⁰, Ulrich Fredberg¹¹, Wolfgang Hartung¹², Alojzija Hočevar¹³, Tanaz A. Kermani¹⁴, Matthew J. Koster¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Møller Døhn¹⁹, Chetan Mukhtyar²⁰, Cristina Ponte²¹, Sofia Ramiro²², Carlo Alberto Scirè²³, Lene Terslev²⁴, Kenneth J. Warrington¹⁵, Bhaskar Dasgupta²⁵ and Wolfgang A. Schmidt²⁶, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁵Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ⁶Rheumatology, MC Groep, Loenga, Netherlands, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ¹⁰Martina Hansens Hospital, Bærum, Oslo, Norway, ¹¹Diagnostic Centre, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark, ¹²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁷Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁰Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²¹Rheumatology Department, Hospital de Santa Maria - Centro Hospital Lisboa Norte, Lisbon, Portugal, ²²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²³Italian Society for Rheumatology, Milan, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²⁵Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ²⁶Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: To test the reliability of recently established consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis…
Abstract Number: 2683 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Carina Mihai¹, Milos Antic², Rucsandra Dobrota³, Diana Bonderman⁴, Harbajan Chadha-Boreham⁵, J. Gerry Coghlan⁶, Christopher Denton⁷, Martin Doelberg⁵, Ekkehard Gruenig⁸, Dinesh Khanna⁹, Vallerie McLaughlin¹⁰, Ulf Müller-Ladner¹¹, Janet E. Pope¹², Daniel M Rosenberg⁵, James R Seibold¹³, Madelon C Vonk¹⁴ and Oliver Distler¹⁵, ¹Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria, ⁵Actelion Pharmaceuticals Ltd., Alschwil, Switzerland, ⁶National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, ⁷Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁸Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany, ⁹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹⁰Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ¹¹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹³Scleroderma Research Consultants LLC, Litchfield, CT, ¹⁴Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), and its diagnosis requires right heart catheterization (RHC). The DETECT study developed…
Abstract Number: 923 • 2017 ACR/ARHP Annual Meeting
Can Education Mitigate the Effect of Poverty on Total Knee Replacement (TKR) Outcomes?
Susan M. Goodman¹, Bella Y. Mehta², Meng Zhang³, Jackie Szymonifka⁴, Iris Navarro-Millán⁵, Joseph T. Nguyen³, Yuo-Yu Lee³, Mark P. Figgie⁶, Michael L. Parks⁶, Shirin A. Dey⁴, Daisy Crego⁴, Linda A. Russell¹, Lisa A. Mandl¹ and Anne R. Bass¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery/Columbia University Mailman School of Public Health, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Health outcomes after total knee replacement (TKR) are generally worse for patients from high poverty neighborhoods. Whether education mitigates the effect of poverty…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Kimberly Morishita¹, Audrea Chen², Cherry Mammen¹, Angelyne Rivera³ and David Cabral¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Medicine, University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Paul Studenic¹, Stephan Blüml¹, Holger Bang², Daniela Sieghart¹, Daniel Aletaha¹, Helmuth Haslacher³, Josef S. Smolen^1,4 and Günter Steiner¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, ⁴Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].